You cannot register for this webinar

Windtree is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. We recently announced positive clinical results of our Phase 2b SEISMiC Extension Study of istaroxime in early cardiogenic shock. Our lead product candidate, istaroxime, is a first-in-class, dual-acting agent being developed in cardiogenic shock and acute heart failure. Our portfolio includes preclinical next generation SERCA2a activators and can potentially be developed for both acute decompensated and chronic out-patient heart failure. Additionally, our pipeline includes a novel, potential high-potency, specific, aPKCi inhibitor with possible broad use in oncology as well as certain rare malignant diseases.